We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DRE
1176
DELISTED
Duke Realty Corp.
DRE
| $115K | ﹤0.01% |
3,359
-1,365
| -29% | -$47.1K |
|
|
CXO
1177
DELISTED
CONCHO RESOURCES INC.
CXO
| $115K | ﹤0.01% |
1,323
-80
| -6% | -$5.77K |
|
1178
Banco Santander
SAN
$200B
| $114K | ﹤0.01% |
29,046
-3,496
| -11% | -$13.6K |
|
1179
Cerus
CERS
$585M
| $113K | ﹤0.01% |
26,978
+668
| +3% | +$2.88K |
|
1180
AeroVironment
AVAV
$7.91B
| $112K | ﹤0.01% |
1,829
+73
| +4% | +$4.37K |
|
1181
Helmerich & Payne
HP
$3.31B
| $112K | ﹤0.01% |
2,504
-2,445
| -49% | -$98.1K |
|
1182
ORIX
IX
$42.8B
| $111K | ﹤0.01% |
6,655
+240
| +4% | +$3.85K |
|
1183
Restaurant Brands International
QSR
$26B
| $111K | ﹤0.01% |
1,750
| – | – |
|
1184
Pan American Silver
PAAS
$18.2B
| $110K | ﹤0.01% |
4,650
+1,000
| +27% | +$18.5K |
|
1185
iShares Silver Trust
SLV
$27.6B
| $110K | ﹤0.01% |
6,600
+800
| +14% | +$13K |
|
1186
ASE Group
ASX
$74.4B
| $109K | ﹤0.01% |
19,777
-712
| -3% | -$3.65K |
|
1187
Intellia Therapeutics
NTLA
$1.52B
| $109K | ﹤0.01% |
7,547
+4,200
| +125% | +$58.4K |
|
1188
Shinhan Financial Group
SHG
$32.8B
| $109K | ﹤0.01% |
2,870
+776
| +37% | +$28.7K |
|
|
ORAN
1189
DELISTED
Orange
ORAN
| $109K | ﹤0.01% |
7,485
+5,247
| +234% | +$82.4K |
|
|
ALEX
1190
DELISTED
Alexander & Baldwin
ALEX
| $107K | ﹤0.01% |
5,133
+807
| +19% | +$18.3K |
|
1191
Pacira BioSciences
PCRX
$1.05B
| $107K | ﹤0.01% |
2,365
-8,187
| -78% | -$348K |
|
1192
Varex Imaging
VREX
$469M
| $107K | ﹤0.01% |
3,626
-1,140
| -24% | -$34.1K |
|
|
DNKN
1193
DELISTED
Dunkin' Brands Group, Inc.
DNKN
| $107K | ﹤0.01% |
1,433
+18
| +1% | +$1.36K |
|
1194
iShares MSCI Pacific ex Japan ETF
EPP
$2.22B
| $106K | ﹤0.01% |
2,304
-755
| -25% | -$34.5K |
|
1195
Helios Technologies
HLIO
$2.56B
| $106K | ﹤0.01% |
2,305
+515
| +29% | +$22.1K |
|
1196
SiteOne Landscape Supply
SITE
$4.58B
| $104K | ﹤0.01% |
1,155
+330
| +40% | +$28K |
|
1197
Assurant
AIZ
$14B
| $103K | ﹤0.01% |
792
| – | – |
|
1198
Coca-Cola Europacific Partners
CCEP
$49.3B
| $103K | ﹤0.01% |
2,035
| – | – |
|
1199
Kayne Anderson Energy Infrastructure Fund
KYN
$2.43B
| $103K | ﹤0.01% |
7,531
-4,162
| -36% | -$55.4K |
|
1200
NewMarket
NEU
$7.2B
| $102K | ﹤0.01% |
211
-28
| -12% | -$13.5K |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.